Quince Therapeutics (NASDAQ:IRLA – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $70.00 price target on the stock. Cantor Fitzgerald‘s price target would suggest a potential upside of 72.46% from the stock’s previous close.
A number of other research analysts also recently weighed in on IRLA. Citizens Jmp upped their price target on Quince Therapeutics from $77.00 to $86.00 and gave the stock a “market outperform” rating in a research note on Monday. Weiss Ratings began coverage on Quince Therapeutics in a research note on Tuesday, October 13th. They issued a “sell (d-)” rating for the company. Citigroup restated a “market outperform” rating on shares of Quince Therapeutics in a report on Tuesday, September 29th. Zacks Research raised Quince Therapeutics to a “hold” rating in a research report on Thursday, October 1st. Finally, Craig Hallum upgraded Quince Therapeutics to a “strong-buy” rating in a report on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $191.00.
Check Out Our Latest Stock Analysis on Quince Therapeutics
Quince Therapeutics Stock Up 5.6%
IRLA opened at $40.59 on Thursday. Quince Therapeutics has a 1-year low of $15.10 and a 1-year high of $909.98. The firm has a market capitalization of $41.40 million, a price-to-earnings ratio of -0.37 and a beta of 1.78.
Quince Therapeutics (NASDAQ:IRLA – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($2.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($1.47). On average, equities analysts predict that Quince Therapeutics will post -9.90 earnings per share for the current year.
Institutional Trading of Quince Therapeutics
An institutional investor recently bought a new position in Quince Therapeutics stock. BlackRock Inc. bought a new stake in Quince Therapeutics, Inc. (NASDAQ:IRLA – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,702 shares of the company’s stock, valued at approximately $31,000. BlackRock Inc. owned approximately 0.17% of Quince Therapeutics as of its most recent SEC filing. Institutional investors own 30.75% of the company’s stock.
Quince Therapeutics Company Profile
Quince Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for rare diseases and other conditions with significant unmet medical needs. The company’s technology platform is designed to use patients’ own red blood cells to deliver therapeutic compounds, with the goal of providing sustained treatment while limiting systemic exposure. Quince’s lead program is the EryDex System, an investigational treatment that loads dexamethasone sodium phosphate into a patient’s red blood cells for controlled release.
Recommended Stories
- Five stocks we like better than Quince Therapeutics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
